Online inquiry

IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13581MR)

This product GTTS-WQ13581MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13581MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9771MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ2956MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ6297MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ7589MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ4031MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ8679MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ2187MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9599MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW